Hormone Response Articles & Analysis
10 news found
Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in individuals living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. ...
The published immunological results are based on the placebo-controlled randomized clinical trial DiAPREV-IT 2, where the safety and efficacy of subcutaneous GAD-alum (Diamyd®) was evaluated in healthy children at risk for clinical type 1 diabetes. The immune response at 18 and 24 months following the last GAD-alum injection showed reduced populations of T-lymphocytes ...
DIAGNODE-B (B for “booster”) assesses the safety, immunological response and clinical effect of an additional intralymphatic injection of Diamyd®. ...
The updated results provide further support to the previously reported topline results that showed a positive immunological and metabolic response to Diamyd® treatment in individuals diagnosed LADA who carries the genetic HLA DR3-DQ2 haplotype. ...
As communicated on December 7, 2021, immunological analyses after 5-months showed that the treatment with Diamyd® induced a clear GAD-specific immune response both in term of antibodies and cell-based reactions in individuals diagnosed with LADA . ...
Analyses also showed a positive immunological response to the treatment and the clinical course appears promising with all individuals remaining insulin-independent 12 months after treatment. ...
Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in individuals living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. ...
Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in individuals living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. ...
ZT-01 is designed to prevent hypoglycemia in people with T1D by restoring the normal glucagon response. Glucagon is a hormone which stimulates the release of glucose from the liver when blood sugar levels drop too ...
ZT-01 is designed to prevent hypoglycemia in people with T1D by restoring the normal glucagon response. Glucagon is a hormone which stimulates the release of glucose from the liver when blood sugar levels drop too ...